Arrowhead's Current Clinical Drug Pipeline - Study Listing - Interactive Chart
Liver Franchise
Date 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
# Drug 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
1 Fazirsiran (Partnered with Takeda) A1AT
Phase 1
Phase 3
Phase 2
Phase 3
Phase 2
Phase 1
2 JNJ-3989 (Licensed to GSK) HBV
Phase 1/2 Phase 2
Phase 2
P1 Phase 2
Ph 1 Ph 1
Ph1
Phase 2
Phase 2
Phase 2
P2
Phase 2
Phase 1
3 Olpasiran (Licensed to Amgen) CV - Lp(a)
Phase 1
Phase 2
Ph 1
Phase 1
Phase 1
Phase 3
4 Zodasiran (ARO-ANG3, VSA003) CV - HoFH, HeFH, MD
Phase 1
Phase 2
Phase 2
Ph 1
5 Plozasiran (ARO-APOC3, VSA001) CV - FCS, sHTG, MD, HTG
Phase 1 Phase 2
Phase 3?
Phase 2
Phase 3?
Phase 3
Phase 2
Phase 1
Phase 3? è
Phase 3
6 GSK4532990 (Licensed to GSK) NASH
Phase 1
Phase 2
Phase 2
7 ARO-PNPLA3 NASH
Phase 1
Phase 1
8 ARO-C3 Comp. Med. Dis.
Phase 1/2
Lung Franchise
Date 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
# Drug 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
1 ARO-RAGE Asthma, COPD, CF
Phase 1/2
Phase 1
2 ARO-MUC5AC Asthma, COPD CF
Phase 1/2
3 ARO-MMP7 IPF
Phase 1/2
CNS Franchise
Date 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
# Drug 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
1 ARO-SOD1 ALS
Phase 1/2
2 ARO-CNS2
(pre-clinical)
Phase 1/2 ?
Muscle Franchise
Date 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
# Drug 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
1 ARO-DUX4 FSHD
Phase 1/2
2 ARO-DM1 DM1
Phase 1/2
Adipose Tissue Franchise
Date 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029
# Drug 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
1 ARO-Adipose1
(pre-clinical)
Phase 1/2 ?
RNAi Platform Clinic Timelines - Current and Dropped Drug Pipeline Candidates - Interactive Chart
2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
10/24/2011 Roche RNAi Asset Acquisition
DPC ARC-520 (P2)
DPC ARC-AAT
A-521 DPC Retired 11/2016
3/5/2015 Novartis RNAi R&D Acquisition
Fazirsiran - AAT (P3) è
JNJ3989 - HBV/HDV (P2) è
Olpasiran (AMG 890) - CV Lp(a) (P3) è
Arrowhead
Zodasiran (ARO-ANG3) - CV (P2b) è
Plozasiran (ARO-APOC3) - CV (P3) è
ARO-HIF2
GSK4532990 - NASH (P2) è
ARO-ENaC
ARO-PNPLA3 - NAFLD (P1) è
ARO-C3 - Comp. Med. (P1) è
ARO-RAGE - Asth/COPD/CF (P1) è
ARO-MUC5AC - Asth/COPD/CF (P1) è
HZN-457 (P1)
ARO-MMP7 - IPF (P1) è
SOD1 - ALS (P1) è
DUX4 - FSHD (P1) è
ARO-DM1 (P1) è